Antiestrogenic Action of Dihydrotestosterone in Mouse Breast
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Affect Breast Cancer Risk
HOW HORMONES AFFECT BREAST CANCER RISK Hormones are chemicals made by the body that control how cells and organs work. Estrogen is a female hormone made mainly in the ovaries. It’s important for sexual development and other body functions. From your first monthly period until menopause, estrogen stimulates normal breast cells. A higher lifetime exposure to estrogen may increase breast cancer risk. For example, your risk increases if you start your period at a young age or go through menopause at a later age. Other hormone-related risks are described below. Menopausal hormone therapy Pills Menopausal hormone therapy (MHT) is The U.S. Food and Drug Administration also known as postmenopausal hormone (FDA) recommends women use the lowest therapy and hormone replacement dose that eases symptoms for the shortest therapy. Many women use MHT pills to time needed. relieve hot flashes and other menopausal Any woman currently taking or thinking symptoms. MHT should be used at the Birth control about taking MHT pills should talk with her lowest dose and for the shortest time pills (oral doctor about the risks and benefits. contraceptives) needed to ease menopausal symptoms. Long-term use can increase breast cancer Vaginal creams, suppositories Current or recent use risk and other serious health conditions. and rings of birth control pills There are 2 main types of MHT pills: slightly increases breast Vaginal forms of MHT do not appear to cancer risk. However, estrogen plus progestin and estrogen increase the risk of breast cancer. However, this risk is quite small alone. if you’ve been diagnosed with breast cancer, vaginal estrogen rings and suppositories are because the risk of Estrogen plus progestin MHT breast cancer for most better than vaginal estrogen creams. -
Degradation and Metabolite Formation of Estrogen Conjugates in an Agricultural Soil
Journal of Pharmaceutical and Biomedical Analysis 145 (2017) 634–640 Contents lists available at ScienceDirect Journal of Pharmaceutical and Biomedical Analysis j ournal homepage: www.elsevier.com/locate/jpba Degradation and metabolite formation of estrogen conjugates in an agricultural soil a,b b,∗ Li Ma , Scott R. Yates a Department of Environmental Sciences, University of California, Riverside, CA 92521, United States b Contaminant Fate and Transport Unit, U.S. Salinity Laboratory, Agricultural Research Service, United States Department of Agriculture, Riverside, CA 92507, United States a r t i c l e i n f o a b s t r a c t Article history: Estrogen conjugates are precursors of free estrogens such as 17ß-estradiol (E2) and estrone (E1), which Received 10 April 2017 cause potent endocrine disrupting effects on aquatic organisms. In this study, microcosm laboratory Received in revised form 11 July 2017 ◦ experiments were conducted at 25 C in an agricultural soil to investigate the aerobic degradation and Accepted 31 July 2017 metabolite formation kinetics of 17ß-estradiol-3-glucuronide (E2-3G) and 17ß-estradiol-3-sulfate (E2- Available online 1 August 2017 3S). The aerobic degradation of E2-3G and E2-3S followed first-order kinetics and the degradation rates were inversely related to their initial concentrations. The degradation of E2-3G and E2-3S was extraordi- Keywords: narily rapid with half of mass lost within hours. Considerable quantities of E2-3G (7.68 ng/g) and E2-3S Aerobic degradation 17ß-estradiol-3-glucuronide (4.84 ng/g) were detected at the end of the 20-d experiment, particularly for high initial concentrations. -
Total Estradiol and Total Testosterone
Laboratory Procedure Manual Analyte: Total Estradiol and Total Testosterone Matrix: Serum Method: Simultaneous Measurement of Estradiol and Testosterone in Human Serum by ID LC-MS/MS Method No: 1033 Revised: as performed by: Clinical Chemistry Branch Division of Laboratory Sciences National Center for Environmental Health contact: Dr. Hubert W. Vesper Phone: 770-488-4191 Fax: 404-638-5393 Email: [email protected] James Pirkle, M.D., Ph.D. Division of Laboratory Sciences Important Information for Users CDC periodically refines these laboratory methods. It is the responsibility of the user to contact the person listed on the title page of each write-up before using the analytical method to find out whether any changes have been made and what revisions, if any, have been incorporated. Total Estradiol and Total Testosterone NHANES 2015-16 Public Release Data Set Information This document details the Lab Protocol for testing the items listed in the following table for SAS file TST_I: VARIABLE NAME SAS LABEL (and SI units) LBXTST Testosterone, total (nmol/L) LBXEST Estradiol (pg/mL) 1 of 49 Total Estradiol and Total Testosterone NHANES 2015-16 Contents 1 Summary of Test Principle and Clinical Relevance 7 1.1 Intended Use 7 1.2 Clinical and Public Health Relevance 7 1.3 Test Principle 8 2 Safety Precautions 10 2.1 General Safety 10 2.2 Chemical Hazards 10 2.3 Radioactive Hazards 11 2.4 Mechanical Hazards 11 2.5 Waste Disposal 11 2.6 Training 11 3 Computerization and Data-System Management 13 3.1 Software and Knowledge Requirements 13 3.2 Sample Information 13 3.3 Data Maintenance 13 3.4 Information Security 13 4 Preparation for Reagents, Calibration Materials, Control Materials, and All Other Materials; Equipment and Instrumentation. -
Estrogen Pharmacology. I. the Influence of Estradiol and Estriol on Hepatic Disposal of Sulfobromophthalein (BSP) in Man
Estrogen Pharmacology. I. The Influence of Estradiol and Estriol on Hepatic Disposal of Sulfobromophthalein (BSP) in Man Mark N. Mueller, Attallah Kappas J Clin Invest. 1964;43(10):1905-1914. https://doi.org/10.1172/JCI105064. Research Article Find the latest version: https://jci.me/105064/pdf Journal of Clinical Investigation Vol. 43, No. 10, 1964 Estrogen Pharmacology. I. The Influence of Estradiol and Estriol on Hepatic Disposal of Sulfobromophthalein (BSP) inMan* MARK N. MUELLER t AND ATTALLAH KAPPAS + WITH THE TECHNICAL ASSISTANCE OF EVELYN DAMGAARD (From the Department of Medicine and the Argonne Cancer Research Hospital,§ the University of Chicago, Chicago, Ill.) This report 1 describes the influence of natural biological action of natural estrogens in man, fur- estrogens on liver function, with special reference ther substantiate the role of the liver as a site of to sulfobromophthalein (BSP) excretion, in man. action of these hormones (5), and probably ac- Pharmacological amounts of the hormone estradiol count, in part, for the impairment of BSP dis- consistently induced alterations in BSP disposal posal that characterizes pregnancy (6) and the that were shown, through the techniques of neonatal period (7-10). Wheeler and associates (2, 3), to result from profound depression of the hepatic secretory Methods dye. Chro- transport maximum (Tm) for the Steroid solutions were prepared by dissolving crystal- matographic analysis of plasma BSP components line estradiol and estriol in a solvent vehicle containing revealed increased amounts of BSP conjugates 10% N,NDMA (N,N-dimethylacetamide) 3 in propylene during estrogen as compared with control pe- glycol. Estradiol was soluble in a concentration of 100 riods, implying a hormonal effect on cellular proc- mg per ml; estriol, in a concentration of 20 mg per ml. -
Low-Dose Vaginal Estrogen Therapy
where it works locally to improve the quality of the skin by normalizing its acidity and making it thicker and better lu- bricated. The advantage of using local therapy rather than systemic therapy (i.e. hormone tablets or patches, etc.) is that much lower doses of hormone can be used to achieve good effects in the vagina, while minimizing effects on Low-Dose Vaginal other organs such as the breast or uterus. Vaginal estrogen comes in several forms such as vaginal tablet, creams or gel Estrogen Therapy or in a ring pessary. Is local estrogen therapy safe for me? A Guide for Women Vaginal estrogen preparations act locally on the vaginal 1. Why should I use local estrogen? skin, and minimal, if any estrogen is absorbed into the bloodstream. They work in a similar way to hand or face 2. What is intravaginal estrogen therapy? cream. If you have had breast cancer and have persistent 3. Is local estrogen therapy safe for me? troublesome symptoms which aren’t improving with vagi- 4. Which preparation is best for me? nal moisturizers and lubricants, local estrogen treatment 5. If I am already on HRT, do I need local estrogen may be a possibility. Your Urogynecologist will coordinate the use of vaginal estrogen with your Oncologist. Studies so as well? far have not shown an increased risk of cancer recurrence in women using vaginal estrogen who are undergoing treat- ment of breast cancer or those with history of breast cancer. Which preparation is best for me? Your doctor will be able to advise you on this but most women tolerate all forms of topical estrogen. -
Feminizing Gender-Affirming Hormone Care the Michigan Medicine Approach
Feminizing Gender-Affirming Hormone Care The Michigan Medicine Approach Our goal is to partner with you to provide the medical care you need in affirming your gender. Our focus is on your lifelong health, safety, and individual medical and transition-related needs. The Michigan Medicine approach is based on the limited but growing medical evidence surrounding gender-affirming hormone care. Based on the available science, we believe mimicking normal physiology will provide you with the best balance of physical and emotional changes and long-term health. This philosophy aligns with current national and international medical guidelines in the care of gender diverse people. We are committed to staying up-to-date with the latest research and medical evidence to ensure you are getting the highest quality care. We know that there are competing approaches to gender-affirming care that are not based on validated scientific evidence. These approaches make scientifically unsubstantiated claims and have unknown short and long-term risks. We are happy to discuss these with you. Below are some answers to questions our patients have asked us about gender- affirming hormone care. We hope the Q&A will help you understand the medical evidence behind our approach to your gender-affirming hormone care, and how it may differ from other approaches, including the approach other well-known clinics in Southeast Michigan. Is there a benefit for monitoring both estrone (E1) and estradiol (E2) levels and aiming for a particular ratio? There are 3 naturally occurring human estrogens: estrone (E1), estradiol (E2), and estriol (E3). Your body naturally balances your estradiol and estrone ratio. -
Hormonal and Immunological Aspects of the Phylogeny of Sex Steroid
Proc. Nati. Acad. Sci. USA Vol. 77, No. 8, pp. 4578-4582, August 1980 Biochemistry Hormonal and immunological aspects of the phylogeny of sex steroid binding plasma protein (estradiol/dihydrotestosterone/a-fetoprotein) JACK-MICHEL RENOIR, CHRISTINE MERCIER-BODARD, AND ETIENNE-EMILE BAULIEU Unite de Recherches sur le Metabolisme Mol6culaire et la Physiopathologie des St6roides de l'Institut National de la Sante et de la Recherche MWdicale, (U 33), Universite Paris-Sud, DMpartement de Chimie Biologique, 78 rue du GUn6ral Leclerc, 94270 Bicetre, France Communicated by Seymour Lieberman, May 5,1980 ABSTRACT Sex steroid binding plasma protein (Sbp) in man acetate, 1:1 (vol/vol) for estradiol. Nonradioactive steroids were and in monkeys binds the androgens dihydrotestosterone and a gift of Roussel-Uclaf (Romainville) (guaranteed 99% testosterone and the estrogen estradiol with high affinity (Kd tO.5, 1, and 2 nM, respectively). Detailed studies of steroid pure). binding specificity give the same results in all primates, except Chemicals and Animals. Tubing [Visking-Nojax, 8/32 in. that in humans and chimpanzees estrone does not compete for (6.4 mm); from Union Carbide Corporation, New York] was dihydrotestosterone binding. In other mammals, Sbps of Arti- used in equilibrium dialyses. Agarose (Indubiose A 37) was odactyla and Lagomorpha have the same range of affinities for purchased from l'Industrie Biologique Francgaise (Paris), Ul- androgens but they do not bind estradiol to any significant ex- trogel AcA 34 was from LKB (Uppsala, Sweden), and Freund's tent (Kd >280 nM). The dog has an unusual Sbp (Kd for dihy- drotestosterone, 7.1 nM; for estiadiol, 125 nM), and rodents do complete and incomplete adjuvants were from Difco. -
OGEN® Estropipate Tablets, USP
PATIENT INFORMATION (Updated July 2006) OGEN® estropipate tablets, USP Read this PATIENT INFORMATION before you start taking OGEN and read what you get each time you refill OGEN. There may be new information. This information does not take the place of talking to your health care provider about your medical condition or your treatment. WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT OGEN (AN ESTROGEN HORMONE)? • Estrogens increase the chances of getting cancer of the uterus. Report any unusual vaginal bleeding right away while you are taking estrogens. Vaginal bleeding after menopause may be a warning sign of cancer of the uterine (womb). Your health care provider should check any unusual vaginal bleeding to find out the cause. • Do not use estrogens with or without progestins to prevent heart disease, heart attacks or strokes. Using estrogens with or without progestins may increase your chances of getting heart attacks, strokes, breast cancer and blood clots. You and your health care provider should talk regularly about whether you still need treatment with OGEN. What is OGEN? OGEN is a medicine that contains estrogen hormones. What is OGEN used for? OGEN is used during and after menopause to: • reduce moderate or severe hot flashes. Estrogens are hormones made by a woman’s ovaries. The ovaries normally stop making estrogens when a woman is between 45 to 55 years old. This drop in body estrogen levels causes the “change of life” or menopause (the end of monthly menstrual periods). Sometimes, both ovaries are removed during an operation before natural menopause takes place. -
Different Levels of Estradiol Are Correlated with Sexual Dysfunction in Adult
www.nature.com/scientificreports OPEN Diferent levels of estradiol are correlated with sexual dysfunction in adult men Tong Chen1,2,3,5, Fei Wu1,4,5, Xianlong Wang2, Gang Ma2, Xujun Xuan2, Rong Tang2, Sentai Ding1 & Jiaju Lu1,2* Ejaculatory dysfunction, including premature ejaculation (PE) and delayed ejaculation (DE), as well as erectile dysfunction (ED), constitute the majority of male sexual dysfunction. Despite a fair amount of data on the role of hormones and erection and ejaculation, it is inconclusive due to controversy in the current literature. To explore the correlation of male sexual dysfunction with hormonal profle, 1,076 men between the ages of 19–60 years (mean: 32.12 years) were included in this retrospective case–control study; 507 were categorized as ED, PE and DE groups. Five hundred and sixty-nine men without sexual dysfunction were enrolled in the control group. The background characteristics and clinical features of the four groups were collected and analyzed. The estradiol value was signifcantly elevated in the ED group than the control group (109.44 ± 47.14 pmol/L vs. 91.88 ± 27.68 pmol/L; P < 0.001). Conversely, the DE group had signifcantly lower level of estradiol than control did (70.76 ± 27.20 pmol/L vs. 91.88 ± 27.68 pmol/L; P < 0.001). The PE group had similar level of estradiol (91.73 ± 31.57 pmol/L vs. 91.88 ± 27.68 pmol/L; P = 0.960) but signifcantly higher level of testosterone (17.23 ± 5.72 nmol/L vs. 15.31 ± 4.31 nmol/L; P < 0.001) compared with the control group. -
Effect of Estrogen on Calcium and Sodium Transport by the Nephron Luminal Membranes
441 Effect of estrogen on calcium and sodium transport by the nephron luminal membranes M G Brunette and M Leclerc Maisonneuve-Rosemont Hospital, Research Center and University of Montreal, Montreal, Quebec, Canada (Requests for offprints should be addressed to M G Brunette, Maisonneuve-Rosemont Hospital, Research Center, 5415, Boulevard de l’Assomption, Montréal, Québec H1T 2 M4, Canada; Email: [email protected] Abstract Estrogens are widely used for contraception and osteo- 0·210·07 pmol/µg per 5 s in vesicles from the control porosis prevention. The aim of the present study was to and treated tubules). Direct incubation of the membranes investigate the effect of 17-estradiol on calcium (Ca2+) with 17-estradiol, however, failed to show any influence transport by the nephron luminal membranes, indepen- of the hormone on Ca2+ transport. The action of 17- dently of any other Ca2+-regulating hormones. Proximal estradiol was dose-dependent, with a half-maximal effect and distal tubules of rabbit kidneys were incubated with at approximately 109 M. Ca2+ uptake by the distal 17-estradiol or the carrier for various periods of time, and tubule membranes presents dual kinetics. 17-Estradiol ffi the luminal membranes of these tubules were purified and decreased the Vmax value of the high-a nity component vesiculated. Ca2+ uptake by membrane vesicles was from 0·420·02 to 0·310·03 pmol/µg per 10 s measured using the Millipore filtration technique. Incu- (P<0·02). In contrast with the effect of the hormone on bation of proximal tubules with the hormone did not Ca2+ transport, estradiol increased Na+ uptake by both influence Ca2+ uptake by the luminal membranes. -
Estrogen Metabolites Are Not Associated with Colorectal Cancer Risk in Postmenopausal Women
Published OnlineFirst June 23, 2015; DOI: 10.1158/1055-9965.EPI-15-0541 Null Results in Brief Cancer Epidemiology, Biomarkers Estrogen Metabolites Are Not Associated with & Prevention Colorectal Cancer Risk in Postmenopausal Women Roni T. Falk1, Cher M. Dallal2, James V. Lacey Jr3, Douglas C. Bauer4, Diana S.M. Buist5, Jane A. Cauley6, Trisha F. Hue7, Andrea Z. LaCroix8, Jeffrey A. Tice4, Ruth M. Pfeiffer9, Xia Xu10, Timothy D. Veenstra11, and Louise A. Brinton1, for the BFIT Research Group Abstract Background: A potential protective role for estrogen in colon at the C-2, C-4, or C-16 position) and by ratios of the groupings carcinogenesis has been suggested based on exogenous hor- using Cox proportional hazards regression models. mone use, but it is unclear from previous studies whether Results: No significant associations were seen for estrone endogenous estrogens are related to colorectal cancer risk. (HRQ4 vs. Q1 ¼ 1.15; 95% CI, 0.69–1.93; Ptrend ¼ 0.54), estradiol These few prior studies focused on parent estrogens; none (HRQ4 vs. Q1 ¼ 0.98; 95% CI, 0.58–1.64; Ptrend > 0.99), or total EM evaluated effects of estrogen metabolism in postmenopausal (the sum of all EM; HRQ4 vs. Q1 ¼ 1.35; 95% CI, 0.81–2.24; Ptrend ¼ women. 0.33). Most metabolites in the 2-, 4-, or 16-pathway were unre- Methods: We followed 15,595 women (ages 55–80 years) lated to risk, although a borderline trend in risk was associated enrolled in the Breast and Bone Follow-up to the Fracture Inter- with high levels of 17-epiestriol. -
Drugs for the Treatment of Menopausal Symptoms
Review Drugs for the treatment of menopausal symptoms † Susan R Davis & Fiona Jane Monash University, Alfred Hospital, Central Clinical School, Women’s Health Program, 1. Introduction Commercial Road, Prahran, Victoria, Australia 2. Which menopausal symptoms Importance of the field: Over the last decade, the management of the meno- merit treatment? pause has attracted extensive public and professional debate and has become 3. Pharmacotherapy for one of the most controversial areas in clinical practice. menopausal symptoms Areas covered in this review: This review provides an overview of the field, 4. New frontiers primarily from a clinical practice perspective. However, as we have incorpo- 5. Expert opinion rated in this ‘big-picture’ snapshot of the field both conventional and comple- mentary approaches to managing the menopause, it is not an exhaustive review of the literature. What the reader will gain: By reviewing menopausal management from the perspective of practicing clinicians, we hope readers will gain insight into decision making processes appropriate for dealing with symptomatic women. Take home message: Although most women do not require pharmacother- apy for menopausal symptoms, many are severely affected by estrogen defi- ciency at and beyond menopause and, for such women, hormone therapy is important if they are to retain an acceptable quality of life. This article consid- ers the drug treatment of the symptomatic postmenopausal woman and the safety issues related to these medications. Keywords: estrogen, HRT, menopause, progestogen Expert Opin. Pharmacother. (2010) 11(8):1329-1341 For personal use only. 1. Introduction Menopause is not only associated with symptoms that range from bothersome through to extremely distressing, it is also accompanied by hormonal changes that impact adversely on several non-reproductive systems.